BSX Stock Price Today (July 2026) — Boston Scientific Corporation Analysis & Key Metrics 2026-07-17
Boston Scientific Corporation (BSX) is trading at $44.03, down 1.32% today (as of July 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $75.00 (70.3% upside).
- Volatility remains elevated (30.91% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (11.60% YoY) alongside significant competitive pressures.
BSX Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Boston Scientific Corporation - Historical Price & Volume
Market Cap
Enterprise Value: $73.25B
P/E Ratio
Forward P/E: 11.47
Revenue Growth
Year over Year
Analyst Target
+70.3% upside potential
Key Investor Questions About BSX
What investors need to know before buying
Based on current market data, BSX presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 44.01)
- Fundamentals say: Caution warranted (high leverage concerns)
BSX's growth trajectory depends on its ability to expand within the Medical Devices sector while managing margin pressures.
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BSX investors include debt exposure and competitive dynamics in the Medical Devices industry.
- $11.03B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
52-Week Trading Range
Over the past year, BSX stock traded between $42.25 and $109.50—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 30.91% annualized volatility and β=0.57, the stock exhibits low sensitivity to market moves—making BSX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Abbott Just Showed Its Growth Engine Has More Than One Cylinder
The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.
J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Why
JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.
Can Abbott Stock Deliver on Its Second-Half Growth Promise?
This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.
Why Abbott Stock Is Reimagining Its Future
Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.
Why Did SPCX, IBM, BSX Drop To 52-Week Lows Today?
SpaceX, IBM and Boston Scientific fell to 52-week lows on Wednesday as Wall Street concerns and profit-taking sent the stocks lower.
Boston Scientific (BSX): Buy, Sell, or Hold Post Q1 Earnings?
Shareholders of Boston Scientific would probably like to forget the past six months even happened. The stock dropped 52.5% and now trades at $42.79. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Boston Scientific (BSX) Faces WATCHMAN Slowdown But Analysts Still See Upside
With an upside potential of 62.55%, Boston Scientific Corporation (NYSE:BSX) is among the 12 Strong Buy Stocks with High Upside According to Analysts. On July 8, Needham analyst Mike Matson lowered the firm’s price target on Boston Scientific Corporation (NYSE:BSX) to $57 from $77 while maintaining a Buy rating on the shares. The adjustment followed management commentary […]
Are Boston Scientific’s (BSX) Sterile-Packaging Recalls Reframing the Narrative on Quality and Regulatory Risk?
Boston Scientific recently initiated several voluntary Class II recalls of its CRE and CRE Pro Wireguided endoscopy devices worldwide due to potential sterile breaches in packaging, affecting tens of thousands of units across multiple size ranges. The recalls underscore the operational and regulatory risks inherent in Boston Scientific’s expanding minimally invasive device portfolio, especially as it integrates recent acquisitions and scales global distribution. We’ll now examine how these...
Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note
In the latest trading session, Boston Scientific (BSX) closed at $42.63, marking a -4.52% move from the previous day.
Intuitive Surgical Pre-Q2 Analysis: Buy, Hold or Sell the Stock Now?
Intuitive Surgical heads into Q2 earnings with strong procedure momentum, da Vinci 5 adoption and expectations for another earnings beat despite margin pressures.
Frequently Asked Questions
Common investor questions about Boston Scientific Corporation
Boston Scientific Corporation (BSX) is currently trading at $44.03. The RSI (14-day) is at 44.0, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $75.00 implies 70.3% upside from current levels. Volatility is moderate at 30.9% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Boston Scientific Corporation (BSX): The trailing P/E ratio is 18.42, which is in line with broader market averages. The forward P/E is 11.47, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.52, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 2.53. Price-to-Sales is 3.17. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 29 analysts covering BSX, the consensus price target is $75.00. This represents a 70.3% upside from the current price of $44.03. The range spans from a low target of $55.00 to a high target of $106.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Boston Scientific Corporation (BSX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Boston Scientific Corporation (BSX) investors include: 1. Moderate volatility (30.9% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Boston Scientific Corporation's (BSX) current debt and financial health profile: Total debt stands at $11.03B. The debt-to-equity ratio is 42.25, which is moderate and generally manageable for most companies. The current ratio is 1.90, indicating strong short-term liquidity. The quick ratio is 0.98. The company holds $1.45B in cash and equivalents. Free cash flow is positive at $2.81B, providing a cushion for debt servicing and shareholder returns.